Isoniazid Prophylaxis in HIV-Infected Patients

HIV-infected patients who received isoniazid preventive therapy as part of a clinical trial in Botswana had low rates of incident tuberculosis and severe adverse events; adherence was quite high.

The WHO currently recommends a 6-month course of isoniazid preventive therapy (IPT) for all HIV-infected patients living in areas with a high prevalence of tuberculosis (TB). However, the uptake, efficacy, and safety of this approach have not been widely studied, and the implementation of IPT programs has lagged. In this report, investigators describe recruitment and initial outcomes from an IPT trial in Botswana, in which HIV-infected patients received open-label isoniazid (plus pyridoxine) for 6 months. The patients were then were randomized to isoniazid or placebo for 30 months, but the results of that intervention have not yet been reported.

Of the 4331 HIV-infected adults who were referred for screening for the trial, only 1995 (46%) we…

Reviewing Author

Shahin Lockman, MD, MSc

Isoniazid Prophylaxis in HIV-Infected Patients

Topics

Reviewing Author